ArticleCadernos de saude publica2025
[Access of children with congenital Zika virus syndrome to public policies].
Article in Cadernos de saude publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The lingering crisis: gaps in long-term care for children with congenital Zika syndrome and their families in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital Zika syndrome (CZS) is responsible for several malformations, including microcephaly. This study aimed to describe children's access to social public policies: lifetime benefit (E60) created in the face of the Zika virus public health emergency (Espin-ZIKV) or Continuous Cash Benefit/Type 87 (BPC/E87). Thus, this study compares the children's access before and after Espin-ZIKV. This was a cross-sectional study, with data extraction and description from the Brazilian Information System on Live Births (SINASC), the Registry of Public Health Events-Microcephaly (Resp-Microcephaly), and the Unified System for Benefits Information (SUIBE), from 2013 to 2021. We describe the E60 that were still active at the time of SUIBE data extraction in May, 2023. We compared the granting of BPC/E87 for microcephaly in 2013 and 2021 (before and after Espin-ZIKV). Of the 20,000,859 live births from 2015-2021, 20,464 suspected cases of CZS were reported in Resp-Microcephaly; 20% of affected patients received some social benefit: 705 received E60 and 3,822 received BPC/E87. The national average of BPC/E87 granted in 2013 for microcephaly was eight for every 100,000 live births (before Espin-ZIKV), while in 2021 it was five BPC/E87 for every 100,000 live births (after Espin-ZIKV) (p < 0.01). We observed 689 children with active E60 (from 3 to 8 years of age), in May, 2023. The study showed low social protection for children with suspected CZS. However, of those who benefited from the E60, 98% had active benefits in 2023, demonstrating the important survival of the benefited children. A reduction in the mean number of BPC/E87 grants for microcephaly without specified cause was observed after Espin-ZIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.